Q Therapeutics, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2026-12: Study NCT02478450; Company role Lead sponsor; Phase Phase 1, Phase 2; Status Not yet recruiting.
- 2022-09-20: Study NCT03887273; Company role Lead sponsor; Phase Phase 1, Phase 2; Status Recruiting.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2026-12 | NCT02478450 Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS) | Lead sponsor | Phase 1, Phase 2 | Not yet recruiting | Amyotrophic Lateral Sclerosis | 30 | 2029-12 |
| 2022-09-20 | NCT03887273 Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis | Lead sponsor | Phase 1, Phase 2 | Recruiting | Transverse Myelitis | 9 | 2028-12 |